Levofloxacin

證據等級: L5

預測適應症: 10 個

Levofloxacin: From Bacterial Infections to Infection Prophylaxis in Monoclonal Gammopathy (Multiple Myeloma)

One-Sentence Summary

Levofloxacin is a third-generation fluoroquinolone antibiotic with broad-spectrum bactericidal activity, established for treating respiratory, urinary, and systemic bacterial infections.

The TxGNN model’s most clinically actionable prediction is Monoclonal Gammopathy — Infection Prophylaxis in Multiple Myeloma (TxGNN rank 7, score 99.81%), supported by the landmark TEAMM Phase 3 RCT (Lancet Oncology, 2019) and 20 publications. A secondary validated use — Septicemic Plague (rank 9) — carries direct FDA approval under the Animal Efficacy Rule. The highest-ranked TxGNN prediction (rank 1: punctate epithelial keratoconjunctivitis, L4) carries only a single case-series publication and a Hold recommendation; clinical focus is directed to the monoclonal gammopathy finding.

Quick Overview

Item	Content
Original Indication	Bacterial infections (community-acquired pneumonia, UTIs, sinusitis, complicated skin infections)
Primary Actionable Prediction	Monoclonal Gammopathy — Infection Prophylaxis in Multiple Myeloma (TxGNN rank 7)
TxGNN Prediction Score	99.81%
Evidence Level	L1
Taiwan Market Status	Not Marketed (未上市)
Number of Authorizations	0 (Taiwan)
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on established pharmacological knowledge, Levofloxacin is a fluoroquinolone antibiotic that exerts bactericidal effects by inhibiting bacterial DNA gyrase (topoisomerase II) and topoisomerase IV — enzymes essential for DNA replication and chromosome segregation. This mechanism produces rapid, concentration-dependent killing of a broad spectrum of pathogens, including Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Escherichia coli, and Staphylococcus aureus — organisms that are the primary culprits in myeloma-associated bacteremia.

Multiple myeloma and related monoclonal gammopathies cause profound humoral immunodeficiency by displacing normal plasma cells, resulting in hypogammaglobulinemia and impaired opsonization. Contemporary induction regimens incorporating bortezomib, thalidomide, lenalidomide, and high-dose dexamethasone further induce lymphocytopenia and neutropenia. Together, these factors create a critical infection-vulnerability window: infections account for 10–15% of myeloma-related deaths, and one in four patients experiences a serious infection within the first 3 months of diagnosis. Levofloxacin’s broad antibacterial coverage addresses precisely this window of risk.

This mechanistic rationale was directly tested in the TEAMM Phase 3 RCT (PMID 31668592, Lancet Oncology 2019), which randomized 977 newly diagnosed myeloma patients to prophylactic levofloxacin 500 mg daily versus placebo for the first 12 weeks of treatment. While the primary composite endpoint (febrile episodes or death at 12 weeks) narrowly missed statistical significance (p=0.10), key secondary endpoints — including incidence of febrile infections, need for intravenous antibiotics, and infection-related hospitalizations — showed meaningful reductions in the levofloxacin arm. The International Myeloma Working Group (IMWG) has subsequently incorporated antibiotic prophylaxis into supportive care guidance for newly diagnosed high-risk patients, citing TEAMM as the primary evidence base.

Clinical Trial Evidence

Currently no registered clinical trials specifically investigating Levofloxacin for monoclonal gammopathy or multiple myeloma infection prophylaxis were identified in ClinicalTrials.gov or ICTRP at the time of this data collection. The evidence base for this indication derives entirely from published randomized trial literature (TEAMM) and multiple prospective and retrospective observational studies documented in the literature section below.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
31668592	2019	Phase 3 RCT	Lancet Oncology	TEAMM trial (N=977): prophylactic levofloxacin in newly diagnosed myeloma reduced febrile infections and IV antibiotic need; primary endpoint p=0.10, secondary endpoints favored levofloxacin; landmark evidence for this indication
31690402	2019	Phase 3 RCT (HTA full report)	Health Technol Assess	Complete TEAMM health technology assessment; comprehensive efficacy, safety, and cost-effectiveness data supporting prophylactic levofloxacin in symptomatic newly diagnosed myeloma
26150022	2015	Prospective observational	Biol Blood Marrow Transplant	Levofloxacin prophylaxis (initiated June 2006) significantly reduced bloodstream infections and febrile neutropenia in MM patients undergoing autologous HSCT; before-after institutional comparison
25212681	2014	Prospective study	Int J Hematology	Oral levofloxacin prophylaxis in MM patients receiving bortezomib-based regimens (high lymphocytopenia risk) reduced severe infectious complications; N=80 evaluable patients
37573150	2023	Retrospective cohort	Transplant Infect Dis	Infectious complications in MM patients post-AHCT with and without levofloxacin prophylaxis; real-world data from developing-country tertiary center; significant post-transplant morbidity from infections highlighted
29080369	2018	Retrospective comparative	Clin Transplantation	N=297 MM patients: ciprofloxacin (N=154) vs. levofloxacin (N=143) prophylaxis in autologous HSCT; compared breakthrough infection rates between the two fluoroquinolones
32304873	2020	Retrospective review	Biol Blood Marrow Transplant	Fluoroquinolone prophylaxis in ASCT: MM patients (institutional levofloxacin policy) vs. lymphoma patients (no prophylaxis); supports value of routine FQ prophylaxis in MM-ASCT setting
32172361	2020	Review	Curr Hematol Malignancy Rep	Comprehensive supportive care review in MM covering bone disease, renal disease, anemia, neuropathy, infections, and VTE; addresses antibiotic prophylaxis in the context of expanding MM survival
24797543	2014	Retrospective before-after	Transplant Infect Dis	Evaluated impact of switching prophylaxis protocol in MM patients undergoing outpatient APBSCT with melphalan; increasing bacterial sepsis with levofloxacin monotherapy prompted protocol change — highlights resistance concern
15791505	2005	Retrospective cohort	Clin Infect Dis	Fluoroquinolone prophylaxis during neutropenia in hematological malignancies associated with decreased gram-negative bacteremia and infection-related mortality; early foundational evidence for this drug class

Taiwan Market Information

No Taiwan TFDA marketing authorizations were identified for Levofloxacin in this Evidence Pack (total licenses: 0, market status: 未上市). Please verify current registration status and obtain the SmPC directly through the TFDA official website (https://www.fda.gov.tw/). Note that Levofloxacin is widely registered and marketed in many other jurisdictions globally under brand names including Levaquin (US) and Tavanic (Europe).

Safety Considerations

Please refer to the SmPC for primary safety information. Based on pharmacological data referenced in the repurposing rationale sections of this evidence pack, the following signals are highlighted for clinical awareness:

Peripheral Neuropathy (FDA Black Box Warning, 2013): Levofloxacin may cause potentially irreversible peripheral neuropathy. This is a critical consideration in myeloma patients, who frequently experience concurrent bortezomib- or thalidomide-induced neuropathy — additive neurotoxicity may occur.
QTc Prolongation: Fluoroquinolone class effect; clinically relevant in myeloma patients receiving concomitant QT-prolonging agents (thalidomide, some antimicrobials). Baseline ECG recommended before initiating prophylaxis.
Tendon Rupture: Class effect; risk is increased in older adults and patients receiving concurrent corticosteroids — both common in myeloma treatment contexts.
Antimicrobial Resistance: Prolonged prophylactic use may select for fluoroquinolone-resistant organisms (ESBL-producing E. coli, FQ-resistant strains). Local antibiogram data should inform the decision to implement prophylaxis, and the program should be embedded within an antimicrobial stewardship framework.
Drug Interaction — Pomalidomide: PMID 25591868 reports a case of acute kidney injury from crystal nephropathy in a myeloma patient receiving pomalidomide and levofloxacin concomitantly; this combination warrants renal monitoring.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The TEAMM Phase 3 RCT (Lancet Oncology, 2019) provides direct clinical validation for prophylactic levofloxacin in newly diagnosed myeloma, and multiple observational studies corroborate the benefit in autologous HSCT settings. The IMWG has incorporated this approach into supportive care guidance. Although the primary endpoint narrowly missed significance (p=0.10), the totality of evidence — biological plausibility, secondary endpoint benefits, guideline recognition, and consistency across multiple independent studies — supports moving forward with clearly defined patient selection and safety monitoring criteria.

To proceed, the following is needed:

Obtain current Taiwan TFDA SmPC to confirm registered indications and complete local contraindication/safety profile
Assess local fluoroquinolone resistance prevalence before implementing a prophylaxis program; high community FQ-resistance rates may negate benefit
Define patient eligibility: newly diagnosed symptomatic multiple myeloma receiving active induction therapy; restrict to the first 12 weeks consistent with the TEAMM protocol
Screen for contraindications prior to initiation: pre-existing peripheral neuropathy (common in myeloma), history of QTc prolongation, personal or family history of tendon disorders, known FQ hypersensitivity
Establish monitoring protocol: baseline neurological assessment and ECG; CBC monitoring during the neutropenic period; renal function monitoring, especially for patients receiving nephrotoxic myeloma therapies
Integrate into antimicrobial stewardship program to track resistance emergence and adjust duration accordingly

Additional Noteworthy Prediction — Septicemic Plague (TxGNN rank 9, L3, Proceed with Guardrails): Levofloxacin received FDA approval in 2012 for plague treatment — including septicemic and pneumonic forms — under the Animal Efficacy Rule, supported by non-human primate (African Green Monkey) studies demonstrating ≥90% efficacy when treatment was initiated within 2–6 hours of fever onset (PMID 21347450, PMID 32435805). Yersinia pestis is highly susceptible to levofloxacin (MIC ≤ 0.03–0.25 μg/mL), and the drug achieves excellent tissue penetration in lung, spleen, and lymph nodes. This represents a regulatory-validated indication relevant to biodefense and bioterrorism preparedness contexts, though human Phase 3 RCT data are unavailable by design.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.